Skip to main content
. 2024 Dec 15;16:17588359241305091. doi: 10.1177/17588359241305091

Figure 4.

Figure 4.

(a) A nomogram designed to predict OS in mUC patients receiving ICIs. (b) A calibration curve of the nomogram for predicting 3-year OS in the training and validation cohorts.

ICI, immune checkpoint inhibitors; mUC, metastatic urothelial carcinoma; OS, overall survival.